Bladder Cancer

Shilpa Gupta, MD, has been appointed director of genitourinary medical oncology at Taussig Cancer Institute and co-leader of the genitourinary oncology program at Cleveland Clinic.

Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large subset of patients with muscle-invasive bladder cancer, according to phase 2 study results.

Genentech voluntarily withdrew atezolizumab’s indication in the United States for patients with platinum-treated metastatic urothelial carcinoma.

Any aspirin use and aspirin use at least three times per week appeared associated with improvements in survival outcomes among older adults with bladder and breast cancers, according to study results published in JAMA Network Open.

AstraZeneca voluntarily withdrew durvalumab’s indication for treatment of adults with locally advanced or metastatic bladder cancer.

Adjuvant nivolumab extended DFS compared with placebo among patients with high-risk, muscle invasive urothelial carcinoma, according to results of the phase 3 CheckMate 274 trial presented at Genitourinary Cancers Symposium.

Elizabeth Plimack, MD, MS, has been appointed chair of Bladder Cancer Advocacy Network’s scientific advisory board.

The FDA granted priority review designation to several therapies in development for hematology/oncology indications.

The FDA granted priority review to durvalumab for administration in a 4-week, fixed dose regimen for the treatment of patients with non-small cell lung cancer and bladder cancer, according to a manufacturer-issued press release.

The FDA approved avelumab for the first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma, according to a press release from the manufacturer.